Acurx Pharmaceuticals Stock Forum

$Acurx Pharmaceuticals(ACXP.US)$ Reuters· 7 mins ago
Uspto Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat Cdi While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

$Acurx Pharmaceuticals(ACXP.US)$
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the USPTO for ibezapolstat, its treatment for C. difficile Infection (CDI). The patent, issued on July 16, 2024, covers ibezapolstat's ability to treat CDI while reducing infection recurrence and improving gut microbiome health. This p...

$Acurx Pharmaceuticals(ACXP.US)$
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
Acurx Pharmaceuticals (NASDAQ: ACXP) presented results from the ibezapolstat Phase 2 clinical trial for C. difficile Infection (CDI) at the 17th Biennial Congress of the Anaerobe Society of the Americas. The study showed favorable gut microbiome changes, including increased Actinobacteria in treated patients. Results were consistent wit...

$Acurx Pharmaceuticals(ACXP.US)$ Reuters· just
Acurx Pharmaceuticals Inc: Agreement With FDA Reached on Key Elements to Move Forward With Our International Phase 3 Clinical Trial Program

$Acurx Pharmaceuticals(ACXP.US)$
NEWS
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.

$Acurx Pharmaceuticals(ACXP.US)$ Acurx Pharmaceuticals Withdraws Filing for Stock Offering
Dow Jones· 7 mins ago

$Acurx Pharmaceuticals(ACXP.US)$ Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

$Acurx Pharmaceuticals(ACXP.US)$ Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
2 MINUTES AGO, 7:00 AM EST
VIA PR NEWSWIRE

$Acurx Pharmaceuticals(ACXP.US)$ Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
4 MINUTES AGO, 7:01 AM EST
VIA PR NEWSWIRE